TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ELI LILLY & CO TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ELI LILLY & CO Stock
Certificat
DE000SW2EQY5
| Market Closed - Deutsche Boerse AG 03:45:37 2024-06-28 pm EDT | ||
| 1.74 EUR | -1.69% |
|
| Current month | -31.76% | ||
| 1 month | -34.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 1.74 | -1.69% |
| 24-06-27 | 1.77 | -2.75% |
| 24-06-26 | 1.82 | +1.11% |
| 24-06-25 | 1.8 | -4.26% |
| 24-06-24 | 1.88 | -4.57% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 03:45 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW2EQY |
| ISIN | DE000SW2EQY5 |
| Date issued | 2023-08-17 |
| Strike | 1,093 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 4.96 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.46 € |
|---|---|
| Lowest since issue | 1.66 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- Certificat
